COEURATIVE, INC.
Novel nitric oxide donor compounds for treating angina pectoris
- Sector
- Biotech
- Headquarters
- ROANOKE, VA
- Founded
- 2012
- Latest Form D
- $100K, Oct 2026
- Total capital
- $920K
- Federal grants
- $300K
- 1 award · 2023
- Rank in peer group#39 of 392
- Private capital raised
- $620K
- 6 Form D · last Oct 2026
- 0 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 2 pending · first 2023
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$100K
- Private capital raisedForm D · SEC · 5th filing$100K
- Federal grantHealth and Human S · Phase I · Novel Coronary Artery Vasodilator Development$300K
- Private capital raisedForm D · SEC · 4th filing$100K
- Private capital raisedForm D · SEC · 3rd filing$100K
- Private capital raisedForm D · SEC · 2nd filing$100K
- Private capital raisedForm D · SEC · 1st filing$120K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#39 · top 10%
- Granted patents#70 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- JOHN F. SCHMEDTJEExecutive OfficerNamed in SEC Form D filings
- John F. Schmedtje, J.rExecutive Officer, DirectorNamed in SEC Form D filings
- John F. Schmedtje, Jr.Executive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 3- GrantedMethods Of Using Nitric Oxide Donor Compounds For Treatment Of COVID-19 And Other Infectious DiseasesUSPTOUS 11,779,560
- PendingNovel Methods Of Using Nitric Oxide Donor Compounds For Treatment Of COVID-19 And Other Infectious DiseasesUSPTOApplication PCTUS2021024540
- PendingNovel Compounds Useful For Treating Cardiovascular DiseasesUSPTOApplication PCTUS2019058241
Related companies, and why
- EXOTECT, LLCSimilar federal contract value in Biotech · null in contracts
- TARGESON, INC.Similar federal contract value in Biotech · null in contracts
- NIGHTHAWK BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Petri Bio LLCSimilar federal contract value in Biotech · null in contracts
- Oncorus, Inc.Similar federal contract value in Biotech · null in contracts
- Valanbio Therapeutics IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .